Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Study of serum sclerostin levels and its role in vascular calcification in patients with chronic kidney disease

The Egyptian Journal of Internal Medicine volume 31, pages 813–821 (2019)Cite this article

A Correction to this article was published on 18 March 2022

This article has been updated

Abstract

Objective

The aim of this work was to study serum sclerostin levels in patients with chronic kidney disease (CKD) not on dialysis and those on regular hemodialysis and its role in vascular calcification.

Background

CKD, whether starting hemodialysis (HD) or not, is associated with an increase in the risk for vascular calcification, which can only be partially explained by known classical risk factors. Sclerostin is an osteocyte-derived inhibitor of the Wnt pathway and has been shown to play a key role in vascular calcification in patients with CKD.

Patients and methods

This cross-sectional study was carried out on 80 patients with CKD attending Menoufia University Hospital. Patients were classified into 40 patients with CKD who were not on HD (group I) and 40 patients with CKD on regular HD more than 6 months (group II), who were compared with 15 controls (group III). Abdominal aortic calcification (AAC) was assessed using lateral lumbar radiography. Echocardiography was used to assess aortic valve calcification (AVC) calcification. Patient’s basic clinical and biochemical data were recorded. Serum sclerostin level was measured using commercially available enzyme-linked immunosorbent assay kits.

Results

Sclerostin levels among the patients with CKD on HD (116.8±0.103.69 Pmol/l) was significantly higher than that of CKD predialysis group (28.63±0.36.26 Pmol/l), which in turn was statistically higher than control group (6.6±0.2.9 Pmol) (P=0.000). AAC was observed in 16 (40%) patients in CKD predialysis group, whereas in CKD on HD group, 26 (65%) patients had AAC. AVC was observed in 14 (35%) patients in CKD predialysis group, whereas in CKD on HD group, 21 (52.5%) patients had AVC. Using binary regression analysis, sclerostin was identified as an independent predictor for the presence of AAC (OR: 1.017; P=0.000) and AVC (OR: 1.013; P=0.001) in patients with CKD.

Conclusion

Patients with CKD (predialysis and on HD) exhibit an increase in sclerostin levels. Sclerostin expansion correlated positively with vascular and valvular calcification. Sclerostin is an independent risk factor for heart valve calcification and AAC in patients with CKD.

Change history

References

  1. Kim Bisson S, Visal Ung V, Way F. Role of the Wnt/β-catenin pathway in renal osteodystrophy. Int J Endocrinol 2018; 2018:5893514.

    Google Scholar 

  2. Zeng C, Guo C, Cai J, Tang C, Dong Z. Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease. Diab Vasc Dis Res 2018; 15:99–105.

    Article  CAS  Google Scholar 

  3. Kidney Disease Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2017; 7:1–59.

    Article  Google Scholar 

  4. Wang XR, Yuan L, Zhang JJ, Hao L, Wang DG. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3–5D. Nephrology 2017; 22:286–292.

    Article  CAS  Google Scholar 

  5. Morena M, Jaussent I, Dupuy A, Bargnoux AS, Kuster N, Chenine L, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant 2015; 30:1345–1356.

    Article  CAS  Google Scholar 

  6. Kanbay M, Solak Y, Siriopol D, Aslan G, Afsar B, Yazici D, et al. Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol 2016; 48:2029–2042.

    Article  CAS  Google Scholar 

  7. Yang CY, Chang ZF, Chau YP, Chen A, Yang WC, Yang AH, et al. Circulating wnt/β-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol Dial Transplant 2015; 30:1356–1363.

    Article  Google Scholar 

  8. Jean G, Chazot C, Bresson E, Zaoui E, Cavalier E. High serum sclerostin levels are associated with a better outcome in haemodialysis patients. Nephron 2016; 132:181–190.

    Article  CAS  Google Scholar 

  9. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 1997; 132:245–250.

    Article  CAS  Google Scholar 

  10. Saran R, Robinson B, Abbott KC, Agodoa LYC, Bhave N, Bragg-Gresham J, et al. Us renal data system 2016 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2017; 69:A7–A8.

    Article  Google Scholar 

  11. Schlieper G, Schurgers L, Brandenburg V, Reutelingsperger C, Floege J. Vascular calcification in chronic kidney disease: an update Nephrol Dial Transplant 2016; 31:31–39.

    Article  CAS  Google Scholar 

  12. Hao L, Chang H, Fu Y, He Z. Vascular and cardiac valve calcification in chronic kidney disease. Atheroscler Open Access 2016; 1:104.

    Google Scholar 

  13. Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6:877–882.

    Article  CAS  Google Scholar 

  14. Drüeke TB, Lafage-Proust MH. Sclerostin: just one more player in renal bone disease? Clin J Am Soc Nephrol 2011; 6:700–703.

    Article  Google Scholar 

  15. Smith ER. Vascular calcification in uremia: New-age concepts about an old-age problem. Kidney Res 2016; 1397:175–208.

    Article  CAS  Google Scholar 

  16. Zhu D, Mackenzie NC, Millan JL, Farquharson C, Mac Rae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011; 6:e19595.

    Article  CAS  Google Scholar 

  17. Wu PC, Zheng CM, Liao MT, Wu CC, Lu KC, Liu WC. Bone turnover and vascular calcification. J Nephrol Ther 2014; 4:171.

    Google Scholar 

  18. Di Lullo L, Barbera V, Bellasi A, Cozzolino M, De Pascalis A, Russo D, et al. Vascular and valvular calcifications in chronic kidney disease: an update. Eur Med J Nephrol 2016; 4:84–91.

    Google Scholar 

  19. Mohamed AA, Helmi AK, Wahab MAKA, Keryakos HK. Correlation of serum sclerostin levels and bone mineral density and vascular calcification in hemodialysis egyptian patients. Int J Med Med Sci 2016; 49:1782.

    Google Scholar 

  20. El-Said G, Abd Albarya M, Bahia A, Elzehryb R, El-Kannishya G. Relation of wnt-signaling antagonist sclerostin to valvular calcification and carotid intimal-medial thickness in hemodialysis patients. J Egypt Soc Nephrol Transplant 2018; 18: 103–111.

    Google Scholar 

  21. Lv W, Guan L, Zhang Y, Yu D, Cao B, Ji Y. Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4. Int Urol Nephrol 2016; 48:2043–2050.

    Article  CAS  Google Scholar 

  22. Ji Y, Guan L, Yu S, Yin P, Shen X, Sun Z, et al. Serum sclerostin as a potential novel biomarker for heart valve calcification in patients with chronic kidney disease. Eur Rev Med Pharmacol Sci 2018; 22:8822–8829.

    PubMed  Google Scholar 

  23. Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H, et al. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab 2014; 99:E1854–E1861.

    Article  CAS  Google Scholar 

  24. Pelletier S, Dubourg L, Carlier M-C., Hadj-Aissa A, Fouque D. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013; 8:819–823.

    Article  CAS  Google Scholar 

  25. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011; 26:373–379.

    Article  Google Scholar 

  26. Urano T, Shiraki M, Ouchi Y, Inoue S. Association of circulating sclerostin levels with fat mass and metabolic disease-related markers in Japanese postmenopausal women. J Clin Endocrinol Metab 2012; 97:1473–1477.

    Article  Google Scholar 

  27. Ishimura E, Okuno S, Okazaki H, Norimine K, Yamakawa K, Yamakawa T, et al. Significant association between bone-specific alkaline phosphatase and vascular calcification of the hand arteries in male hemodialysis patients. Kidney Blood Press Res 2014; 39:299–307.

    Article  CAS  Google Scholar 

  28. Dhakshinamoorthy J, Elumalai R, Dev B, Hemamalini A, VenkataSai P, Periasamy S. Assessment of abdominal aortic calcification in predialysis chronic kidney disease and maintenance hemodialysis patients. Saudi J Kidney Dis Transpl 2017; 28:1338–1348.

    Article  Google Scholar 

  29. Evenepoel P, D’Haese P, Brandenburg V. Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int 2015; 88:235–240.

    Article  CAS  Google Scholar 

  30. Claes KJ, Viaene L, Heye S, Meijers B, d’Haese P, Evenepoel P. Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 2013; 98:3221–3228.

    Article  CAS  Google Scholar 

  31. Kirkpantur A, Balci M, Turkvatan A, Afsar B. Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients. Nefrologia 2016; 36:24–32.

    Article  Google Scholar 

  32. Novo-Rodríguez C, García-Fontana B, Andújar-Vera F, Ávila-Rubio V, García-Fontana C, Morales-Santana S, et al. Circulating levels of sclerostin are associated with cardiovascular mortality. PLoS One 2018; 13:e0199504.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine Department, Faculty of Medicine, Menoufia University, Shebeen Elkom, Menoufia, Egypt

    Ahmed R. Elarbagy, Yassein S. Yassein, Mahmoud M. Emara, Khaled M. A. Elzorkany & Amera A. Sharaf El Deen MD

  2. Clinical Pathology Department, Faculty of Medicine, Menoufia University, Shebeen Elkom, Menoufia, Egypt

    Ahmed A. Sonbol

Authors
  1. Ahmed R. Elarbagy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yassein S. Yassein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mahmoud M. Emara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmed A. Sonbol
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Khaled M. A. Elzorkany
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amera A. Sharaf El Deen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amera A. Sharaf El Deen MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

The original online version of this article was revised to correct the fifth author’s name.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elarbagy, A.R., Yassein, Y.S., Emara, M.M. et al. Study of serum sclerostin levels and its role in vascular calcification in patients with chronic kidney disease. Egypt J Intern Med 31, 813–821 (2019). https://doi.org/10.4103/ejim.ejim_34_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_34_19

Keywords